Early treatment of heart failure: a non-interventional observational study of patients with heart failure and initiated on dapagliflozin in Portugal
n/a - n/a
Endpoint Classification: -
Intervention Model: -
Primary Purpose: -
Verified 01 May 2023 by AstraZeneca
No locations available
Patients who have initiated treatment with dapagliflozin for HFrEF between 1st of March 2021 and 31st of October 2021 (prior to study initiation date).
Patients who have started treatment with dapagliflozin for HFrEF from 1st April 2022 onwards. At least 30 days must have elapsed (but no more than 60 days) from first prescription of dapagliflozin before a patient can be enrolled.